Agios Pharmaceuticals Inc stock is traded at $29.74, with a volume of 10,235. It is up +0.20% in the last 24 hours and down -14.79% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Previous Close:
$29.68
Open:
$29.93
24h Volume:
10,235
Relative Volume:
0.01
Market Cap:
$1.78B
Revenue:
$66.05M
Net Income/Loss:
-$422.60M
P/E Ratio:
-
EPS:
-$7.25
Net Cash Flow:
-$384.73M
1W Performance:
-6.36%
1M Performance:
-14.79%
6M Performance:
+7.25%
1Y Performance:
+33.12%
1-Day Range:
$29.51$30.31
1-Week Range:
$28.95$31.97
52-Week Range:
$22.24$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
617-649-8600Address
88 SIDNEY STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS